871 related articles for article (PubMed ID: 23541756)
1. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Miller TM; Pestronk A; David W; Rothstein J; Simpson E; Appel SH; Andres PL; Mahoney K; Allred P; Alexander K; Ostrow LW; Schoenfeld D; Macklin EA; Norris DA; Manousakis G; Crisp M; Smith R; Bennett CF; Bishop KM; Cudkowicz ME
Lancet Neurol; 2013 May; 12(5):435-42. PubMed ID: 23541756
[TBL] [Abstract][Full Text] [Related]
2. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
[TBL] [Abstract][Full Text] [Related]
3. Trial of Antisense Oligonucleotide Tofersen for
Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.
McCampbell A; Cole T; Wegener AJ; Tomassy GS; Setnicka A; Farley BJ; Schoch KM; Hoye ML; Shabsovich M; Sun L; Luo Y; Zhang M; Comfort N; Wang B; Amacker J; Thankamony S; Salzman DW; Cudkowicz M; Graham DL; Bennett CF; Kordasiewicz HB; Swayze EE; Miller TM
J Clin Invest; 2018 Aug; 128(8):3558-3567. PubMed ID: 30010620
[TBL] [Abstract][Full Text] [Related]
10. [Amyotrophic lateral sclerosis with the SOD1 mutations].
Aoki M; Warita H; Itoyama Y
Rinsho Shinkeigaku; 2008 Nov; 48(11):966-9. PubMed ID: 19198133
[TBL] [Abstract][Full Text] [Related]
11. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.
Lange DJ; Shahbazi M; Silani V; Ludolph AC; Weishaupt JH; Ajroud-Driss S; Fields KG; Remanan R; Appel SH; Morelli C; Doretti A; Maderna L; Messina S; Weiland U; Marklund SL; Andersen PM
Ann Neurol; 2017 Jun; 81(6):837-848. PubMed ID: 28480639
[TBL] [Abstract][Full Text] [Related]
12. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.
Winer L; Srinivasan D; Chun S; Lacomis D; Jaffa M; Fagan A; Holtzman DM; Wancewicz E; Bennett CF; Bowser R; Cudkowicz M; Miller TM
JAMA Neurol; 2013 Feb; 70(2):201-7. PubMed ID: 23147550
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
15. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
16. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
Wills AM; Hubbard J; Macklin EA; Glass J; Tandan R; Simpson EP; Brooks B; Gelinas D; Mitsumoto H; Mozaffar T; Hanes GP; Ladha SS; Heiman-Patterson T; Katz J; Lou JS; Mahoney K; Grasso D; Lawson R; Yu H; Cudkowicz M;
Lancet; 2014 Jun; 383(9934):2065-2072. PubMed ID: 24582471
[TBL] [Abstract][Full Text] [Related]
17. [Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor].
Aoki M; Warita H; Suzuki N; Itoyama Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):814-7. PubMed ID: 20030218
[TBL] [Abstract][Full Text] [Related]
18. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ
Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116
[TBL] [Abstract][Full Text] [Related]
19. Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis.
Zhang C; Zhou C; Teng JJ; Zhao RL; Song YQ; Zhang C
Cytotherapy; 2009; 11(3):299-306. PubMed ID: 19333801
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.
Ochs G; Penn RD; York M; Giess R; Beck M; Tonn J; Haigh J; Malta E; Traub M; Sendtner M; Toyka KV
Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Jun; 1(3):201-6. PubMed ID: 11464953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
